Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

News

 

Mid Europa pulls Regina Maria sale

PE firm Mid Europa has pulled the sale of its Romanian healthcare provider Regina Maria, but may re-launch it in the second half of 2021.

Delays in Oman for insurance and hospital construction

Private providers in Oman are still awaiting the introduction of mandatory insurance a year after the country's Capital Market Authority said it would be introduced. Experts suggest a new timeline of Q2 2020 but could construction news also point to further problems in both the public and private healthcare sectors?

NMC shares drop yet again after key shareholders sell

Two of the largest shareholders in under-fire UAE-based NMC Healthcare have sold a stake in the beleaguered FTSE 100 company, shares in which plummeted 18% overnight at the announcement between close of trading Tuesday, January 7 and opening on Wednesday, January 8.

Icade eyeing Spanish investment

French property investor Icade Santé is looking to enter Spain this year, while growing its business in Germany and Italy. We discuss strategy with the company's head of healthcare.

Pension fund leads KRY’s €140m Series C

Canada's largest single-profession pension fund has become the lead investor in the KRY's €140m Series C funding round. HBI speculates on the investment, the valuation and future plans of Europe's largest digital health player.

Circle and MPT take over BMI Healthcare

UK hospital group Circle Health is acquiring competitor BMI Healthcare, confirming HBI's earlier exclusive report, while international healthcare REIT Medical Properties Trust (MPT) is buying the bulk of the real estate. We talk to UK advisors and crunch the numbers of the deal.

SpaMedica up for sale (again)

HBI hears ophthalmic specialist SpaMedica, the largest UK NHS cataract surgery provider, is back up for sale just two months after it was pulled from the market. HBI speaks to a UK based market expert to find out more, and about how the group continues to carve out a growing niche for itself, and speculates on price and multiple.

Find Us